We can control inflammation in RA, but some pts still struggle with disease impact, despite improving with bDMARDs: - lower inflamm - higher comorbidities Doesn’t necessarily map to fibromyalgia dx Beyond Rx, this is the critical question CareRA/2000 #EULAR2025 OP0330 @RheumNow https://t.co/Th3smMgtVb